EW SEC Filing News — Edwards Lifesciences Corporation

Latest SEC filings for Edwards Lifesciences Corporation (EW) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-08.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provide…
Sector: Healthcare Industry: Medical Devices Market Cap: $50.3B CIK: 1099800
20
Total Filings
0
Bullish Classifications
8
Bearish Classifications
11
Insider Transactions
1
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for EW currently lean bearish. Of the 20 filing records displayed, 8 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
EW Filing Activity Snapshot 2026-07-30 — 2026-10-08
Insider Transactions (Form 4)
0 buys vs 8 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$4.62M
Ullem Scott B. · 2026-07-30
50,000 shares · Form 144
Form 144 Notices
7
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Edwards Lifesciences Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 8 open-market sale and 3 tax withholding. 8 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×8
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Tax withholding ×3
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Form 4 Open-market sale Insider Selling 2026-10-08

EW insider Lippis Daniel J. (CVP, TAVR) sold 619 shares (~$53.0K)

Lippis Daniel J., listed as CVP, TAVR at Edwards Lifesciences Corp, reported an open-market sale of 619 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 619 $72.68 $45.0K
S Open-market sale 619 $85.65 $53.0K
M Option exercise derivative · Employee Stock Option (Right to Acquire) 619 — —
Filing: Form 4 (Insider Transaction) Insider: Lippis Daniel J. (CVP, TAVR) Shares: 619 Est. Value: $53.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-14

EW insider Form 4 filed for equity award, exercise, or tax withholding

Markowitz Wayne (CVP, JAPAC) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 355 $86.77 $30.8K
F Tax withholding on vested shares 568 $84.37 $47.9K
Filing: Form 4 (Insider Transaction) Insider: Markowitz Wayne (CVP, JAPAC) Shares: 923
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-14

EW insider Form 4 filed for equity award, exercise, or tax withholding

Dahl Andrew M. (SVP, Corporate Controller) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 253 $84.37 $21.3K
Filing: Form 4 (Insider Transaction) Insider: Dahl Andrew M. (SVP, Corporate Controller) Shares: 253
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-11

EW insider Form 4 filed for equity award, exercise, or tax withholding

Chopra Daveen (CVP, TMTT, Surgical & IHFM) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 398 $86.77 $34.5K
Filing: Form 4 (Insider Transaction) Insider: Chopra Daveen (CVP, TMTT, Surgical & IHFM) Shares: 398
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-11

EW insider Lippis Daniel J. (CVP, TAVR) sold 619 shares (~$54.2K)

Lippis Daniel J., listed as CVP, TAVR at Edwards Lifesciences Corp, reported an open-market sale of 619 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 619 $72.68 $45.0K
S Open-market sale 619 $87.51 $54.2K
M Option exercise derivative · Employee Stock Option (Right to Acquire) 619 — —
Filing: Form 4 (Insider Transaction) Insider: Lippis Daniel J. (CVP, TAVR) Shares: 619 Est. Value: $54.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-31

EW insider Dahl Andrew M. (SVP, Corporate Controller) sold 544 shares (~$49.5K)

Dahl Andrew M., listed as SVP, Corporate Controller at Edwards Lifesciences Corp, reported an open-market sale of 544 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 544 $91.06 $49.5K
Filing: Form 4 (Insider Transaction) Insider: Dahl Andrew M. (SVP, Corporate Controller) Shares: 544 Est. Value: $49.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-28

EW insider Bruls Annette (CVP, EMEACLA) sold 2,644 shares (~$237.9K)

Bruls Annette, listed as CVP, EMEACLA at Edwards Lifesciences Corp, reported an open-market sale of 2,644 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,644 $89.98 $237.9K
Filing: Form 4 (Insider Transaction) Insider: Bruls Annette (CVP, EMEACLA) Shares: 2,644 Est. Value: $237.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-26

EW insider Chopra Daveen (CVP, TMTT, Surgical & IHFM) sold 31,800 shares (~$2.89M)

Chopra Daveen, listed as CVP, TMTT, Surgical & IHFM at Edwards Lifesciences Corp, reported an open-market sale of 31,800 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 31,800 $72.68 $2.31M
S Open-market sale 1,154 $91.76 $105.9K
S Open-market sale 30,646 $90.99 $2.79M
M Option exercise derivative · Employee Stock Option (Right to Acquire) 31,800 — —
Filing: Form 4 (Insider Transaction) Insider: Chopra Daveen (CVP, TMTT, Surgical & IHFM) Shares: 31,800 Est. Value: $2.89M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-26

EW insider Markowitz Wayne (CVP, JAPAC) sold 1,240 shares (~$113.4K)

Markowitz Wayne, listed as CVP, JAPAC at Edwards Lifesciences Corp, reported an open-market sale of 1,240 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,240 $91.47 $113.4K
Filing: Form 4 (Insider Transaction) Insider: Markowitz Wayne (CVP, JAPAC) Shares: 1,240 Est. Value: $113.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-11

EW insider Lippis Daniel J. (CVP, TAVR) sold 619 shares (~$57.0K)

Lippis Daniel J., listed as CVP, TAVR at Edwards Lifesciences Corp, reported an open-market sale of 619 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 619 $72.68 $45.0K
S Open-market sale 619 $92.03 $57.0K
M Option exercise derivative · Employee Stock Option (Right to Acquire) 619 — —
Filing: Form 4 (Insider Transaction) Insider: Lippis Daniel J. (CVP, TAVR) Shares: 619 Est. Value: $57.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-30

EW insider Markowitz Wayne (CVP, JAPAC) sold 146 shares (~$12.6K)

Markowitz Wayne, listed as CVP, JAPAC at Edwards Lifesciences Corp, reported an open-market sale of 146 EW shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 146 $86.03 $12.6K
Filing: Form 4 (Insider Transaction) Insider: Markowitz Wayne (CVP, JAPAC) Shares: 146 Est. Value: $12.6K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 7 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Edwards Lifesciences Corporation has 7 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-31

EW Form 144 filed for proposed insider sale by Dahl Andrew M. (544 shares) ~$49.5K

Dahl Andrew M. filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Dahl Andrew M. Shares: 544 Est. Value: $49.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-28

EW Form 144 filed for proposed insider sale by Bruls Annette (2,644 shares) ~$237.9K

Bruls Annette filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Bruls Annette Shares: 2,644 Est. Value: $237.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-26

EW Form 144 filed for proposed insider sale by Markowitz Wayne (1,240 shares) ~$113.4K

Markowitz Wayne filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Markowitz Wayne Shares: 1,240 Est. Value: $113.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-26

EW Form 144 filed for proposed insider sale by Chopra Daveen (31,800 shares) ~$2.89M

Chopra Daveen filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Chopra Daveen Shares: 31,800 Est. Value: $2.89M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-11

EW Form 144 filed for proposed insider sale by Lippis Daniel J. (1,857 shares) ~$170.9K

Lippis Daniel J. filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Lippis Daniel J. Shares: 1,857 Est. Value: $170.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-30

EW Form 144 filed for proposed insider sale by Ullem Scott B. (50,000 shares) ~$4.62M

Ullem Scott B. filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Ullem Scott B. Shares: 50,000 Est. Value: $4.62M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-30

EW Form 144 filed for proposed insider sale by Markowitz Wayne (147 shares) ~$12.6K

Markowitz Wayne filed a Form 144 with the SEC indicating intent to sell EW (Edwards Lifesciences Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Markowitz Wayne Shares: 147 Est. Value: $12.6K
View on SEC EDGAR → Open Filing Document →
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Edwards Lifesciences Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-28

EW filed 8-K — material company event

Edwards Lifesciences Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Edwards Lifesciences Corporation.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

EW filed Quarterly Report (10-Q)

Edwards Lifesciences Corp filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Edwards Lifesciences Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on EW. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — EW SEC Filings

More Tools for EW

EW Full Stock Analysis EW Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper EW analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the EW stock analysis page.

EW Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer